Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan simulated driving performance in healthy volunteers
NCT03012334Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Standard Deviation of Lateral Position. Started Jan 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03012334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012334.